吸入激素联合噻托溴铵治疗哮喘-慢阻肺重叠综合征的临床疗效评价  

Evaluation of clinical effect by inhaled corticosteroid combined with tiotropium bromide in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome

作　　者：尚愚[1] 蔡娜[1] 

机构地区：[1]黑龙江哈尔滨市第一医院呼吸内二科,150010

出　　处：《中国实用医药》2017年第11期104-105,共2页China Practical Medicine

摘　　要：目的探讨吸入激素联合噻托溴铵治疗哮喘-慢阻肺重叠综合征临床效果。方法 124例哮喘-慢阻肺重叠综合征患者随机分为对照组和实验组,各62例。对照组实施布地奈德粉吸入剂激素吸入治疗;实验组采用吸入激素联合噻托溴铵治疗;对比分析两组患者治疗前后吸气分数(IC/TLC)、残总比(RV/TLC)和第一秒用力呼气容积(FEV1)和并发症的发生率。结果两组治疗前IC/TLC、RV/TLC、FEV1对比差异无统计学意义(P>0.05)。在治疗后,实验组IC/TLC和FEV1均显著高于对照组,差异具有统计学意义(t=11.861、12.653,P<0.05);实验组RV/TLC显著低于对照组,差异具有统计学意义(t=9.442,P<0.05)。实验组并发症发生率为4.84%,显著低于对照组的32.26%,差异具有统计学意义(P<0.05)。结论在哮喘-慢阻肺重叠综合征临床治疗中,吸入激素联合噻托溴铵体现出较好的临床效果,能够显著的改善患者的肺功能,减少并发症的发生率,在临床中具有推广应用价值。Objective To investigate clinical effect by inhaled corticosteroid combined with tiotropium bromide in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome. Methods A total of 124 patients with asthma-chronic obstructive pulmonary disease overlap syndrome were randomly divided into control group and experimental group, with 62 cases in each group. The control group received budesonide powder for inhalation, and the experimental group received inhaled corticosteroid combined with tiotropium bromide for treatment. Comparative analysis was made on inspiratory fraction （IC/TLC）, residual and total ratio （RV/TLC）, forced expiratory volume in 1 second （FEV1） and incidence of complications between the two groups. Results There was no statistically significant difference of IC/TLC, RV/TLC and FEV1 before treatment between the two groups （P〉O.05）. After treatment, the experimental group had obviously higher IC/TLC and FEV1 than the control group, and their difference had statistical significance （t=l 1.861, 12.653, P〈0.05）. The experimental group had much lower RV/TLC than the control group, and the difference had statistical significance （t=9.442, P〈0.05）. The experimental group had much lower incidence of complications as 4.84% than 32.26% in the control group, and the difference had statistical significance （P〈0.05）. Conclusion In clinical treatment of asthma-chronic obstructive pulmonary disease overlap syndrome, inhaled corticosteroid combined with tiotropium bromide shows excellent clinical effect. It can remarkably improve pulmonary function and lower incidence of complications in patients. This method contains value for clinical promotion and application.

关 键 词：哮喘-慢阻肺重叠综合征 吸入激素 噻托溴铵 并发症发生率 

分 类 号：R562.25[医药卫生—呼吸系统] R563.9[医药卫生—内科学]